Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. The newly developed biologic itolizumab is a humanized recombinant anti-CD6 monoclonal antibody of IgG1 isotype that binds to domain 1 of CD6, thereby immunomodulating human lymphocytes without interfering with the binding of CD6 to the activated leukocyte-cell adhesion molecule. In this case series, a total of 5 patients with chronic plaque psoriasis were treated with itolizumab. They exhibited a rapid PASI 75 response after 4 doses of itolizumab infusion. The patients were poor responders to methotrexate and/or cyclosporine therapy for a long time. All infusions were well tolerated by all patients with no adverse reactions or infections during the treatment period. Itolizumab can be a good option for management of psoriasis and psoriatic arthritis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Case Reports in Dermatology - 9(2017), 2, Seite 141-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ganesh Pai [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1159/000475519 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ028606965 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ028606965 | ||
| 003 | DE-627 | ||
| 005 | 20230502150046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000475519 |2 doi | |
| 035 | |a (DE-627)DOAJ028606965 | ||
| 035 | |a (DE-599)DOAJd2377a7846f340f8acc0b8a41560c0f3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RL1-803 | |
| 100 | 0 | |a Ganesh Pai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. The newly developed biologic itolizumab is a humanized recombinant anti-CD6 monoclonal antibody of IgG1 isotype that binds to domain 1 of CD6, thereby immunomodulating human lymphocytes without interfering with the binding of CD6 to the activated leukocyte-cell adhesion molecule. In this case series, a total of 5 patients with chronic plaque psoriasis were treated with itolizumab. They exhibited a rapid PASI 75 response after 4 doses of itolizumab infusion. The patients were poor responders to methotrexate and/or cyclosporine therapy for a long time. All infusions were well tolerated by all patients with no adverse reactions or infections during the treatment period. Itolizumab can be a good option for management of psoriasis and psoriatic arthritis. | ||
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Itolizumab | |
| 650 | 4 | |a Psoriatic arthritis | |
| 653 | 0 | |a Dermatology | |
| 700 | 0 | |a Anusha H. Pai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Case Reports in Dermatology |d Karger Publishers, 2009 |g 9(2017), 2, Seite 141-145 |w (DE-627)DOAJ000059439 |x 16626567 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2017 |g number:2 |g pages:141-145 |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000475519 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d2377a7846f340f8acc0b8a41560c0f3 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.karger.com/Article/FullText/475519 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1662-6567 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2017 |e 2 |h 141-145 | ||